---
title: "Vor Bio grants stock options for 32,550 shares, RSUs for 6,900 shares to new hires under inducement plan"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294736248.md"
description: "Vor Biopharma granted inducement equity awards to five new hires on August 1, 2026. The package includes stock options for 32,550 shares at $21.15 and RSUs for 6,900 shares. Both instruments vest over four years, with 25% vesting after 12 months."
datetime: "2026-08-03T20:39:59.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294736248.md)
  - [en](https://longbridge.com/en/news/294736248.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294736248.md)
generator: "portal-rs"
---

# Vor Bio grants stock options for 32,550 shares, RSUs for 6,900 shares to new hires under inducement plan

-   Vor Bio granted inducement equity awards on Aug. 1, 2026 to five new hires under its 2023 Inducement Plan. \* Awards include stock options for 32,550 shares, priced at USD 21.15, matching the grant-date close; options run 10 years. \* RSUs cover 6,900 shares; both options and RSUs vest over four years, with 25% after 12 months. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vor Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608031630PRIMZONEFULLFEED9802488) on August 03, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [VOR.US](https://longbridge.com/en/quote/VOR.US.md)

## Related News & Research

- [Vor Bio files automatic mixed securities shelf](https://longbridge.com/en/news/298086293.md)
- [Vor Bio grants 83,600 stock options, 17,900 RSUs to new hires under inducement plan](https://longbridge.com/en/news/298071325.md)
- [Vor Bio completes enrollment in Phase 3 UPSTREAM MG trial for telitacicept in generalized myasthenia gravis](https://longbridge.com/en/news/298307070.md)
- [Vor Bio highlights telitacicept BAFF/APRIL inhibitor as lead program in B cell-driven autoimmune diseases](https://longbridge.com/en/news/298307942.md)
- [Vor Bio grants inducement awards to new hires, including options for 71,200 shares at $18.39](https://longbridge.com/en/news/291592170.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**